ASYS vs AUDC

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of just 2/9 indicating weak financial health. Despite strong recent price momentum and a single analyst strong_buy recommendation, the company is unprofitable (profit margin -38.21%, ROE -44.68%), experiencing declining revenues (YoY -17.70%), and lacks meaningful valuation benchmarks due to missing Altman Z-Score and Graham Number. While liquidity ratios are healthy and insider sentiment is neutral, the combination of poor profitability, inconsistent earnings, and elevated forward P/E of 68.62 suggests significant overvaluation risk. The stock's recent price surge appears disconnected from fundamentals, increasing vulnerability to correction.

The company exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, limiting distress risk assessment. While profitability metrics like gross margin and ROE are relatively solid, growth is sluggish and valuation multiples are mixed. The stock trades above the Graham Number of $7.99 but below the intrinsic value estimate of $9.71, suggesting modest undervaluation. However, weak earnings consistency, declining price trends, and low analyst coverage temper optimism.